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After albumin, immunoglobulin G (IgG) are the most abundant proteins in human serum, 
with IgG1 and IgG3 being the most abundant subclasses directed against protein anti-
gens. The quality of the IgG-Fc-glycosylation has important functional consequences, 
which have been found to be skewed toward low fucosylation in some antigen-specific 
immune responses. This increases the affinity to IgG1-Fc-receptor (FcγR)IIIa/b and 
thereby directly affects downstream effector functions and disease severity. To date, 
antigen-specific IgG-glycosylation have not been analyzed for IgG3. Here, we analyzed 
30 pregnant women with anti-K alloantibodies from a prospective screening cohort and 
compared the type of Fc-tail glycosylation of total serum- and antigen-specific IgG1 and 
IgG3 using mass spectrometry. Total serum IgG1 and IgG3 Fc-glycoprofiles were highly 
similar. Fc glycosylation of antigen-specific IgG varied greatly between individuals, but 
correlated significantly with each other for IgG1 and IgG3, except for bisection. However, 
although the magnitude of changes in fucosylation and galactosylation were similar for 
both subclasses, this was not the case for sialylation levels, which were significantly 
higher for both total and anti-K IgG3. We found that the combination of relative IgG1 and 
IgG3 Fc-glycosylation levels did not improve the prediction of anti-K mediated disease 
over IgG1 alone. In conclusion, Fc-glycosylation profiles of serum- and antigen-specific 
IgG1 and IgG3 are highly similar.
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inTrODUcTiOn
Immunoglobulins are the backbone of the adaptive humoral immune response generally formed to 
foreign antigens on pathogens and providing protection (1). However, we can also mount immune 
responses against foreign antigens found in other individuals of the same species (alloimmuniza-
tion, frequently occurring during pregnancy or blood transfusion) or self-antigens, promoting 
allo- or autoimmune diseases, respectively. In cases of maternal immunization against red cells 
(RBC), only the immunoglobulin G (IgG) isotype can cross the placenta. These alloantibodies can 
cause destruction of RBCs in the fetus or newborn in reticuloendothelial cells in the spleen and/or 
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Kupffer cells in the liver. This results in hemolytic disease of the 
fetus and newborn (HDNF), a potentially life-threatening disease 
(2). However, the potency of red cell antibodies to induce HDFN 
differs and depends on several factors including IgG subclass, 
specificity of the red cell antibodies, and level of expression on 
the fetal red cells and other tissues (2). HDFN caused by anti-D 
antibodies is well known, but may also occur due to other RBC 
antibody specificities, with anti-K, anti-c, and anti-E being most 
frequently implicated (3, 4). Severe HDFN, resulting in neonatal/
fetal death or the need for a blood transfusion during pregnancy 
or within 1 week after delivery, most often occurs due to anti-D 
(33%), anti-K (26%), followed by anti-c (10%) and anti-E (2%) 
(2). Besides direct destruction of fetal red cells, anti-K antibodies 
can suppress erythropoiesis since—unlike the Rh antigens—K is 
also expressed on early RBC progenitors (5). Fetal anemia can 
lead to fetal hepatosplenomegaly as a result of compensatory 
erythropoiesis, hyperbilirubinemia due to fetal hemolysis, jaun-
dice, kernicterus, or even fetal death (6).
Immunoglobulin G can be further divided into four sub-
classes: IgG1, IgG2, IgG3, and IgG4, which are produced in 
different amounts in response to antigens. Human IgG contains 
one highly conserved N-linked glycosylation site at position 297 
which influences the interaction with FcγRs and C1q and thereby 
influence pro- and anti-inflammatory immune responses (7–13). 
This N-linked glycan consists of a biantennary glycan but varies 
widely in the exact structure. Each glycan on one of the two heavy 
chains carries zero, one or two galactoses, the majority contains 
a core fucose, a minority carries a bisecting N-acetylglucosamine 
(GlcNAc) (bisection), and one or two sialic acids may be attached 
on top of the galactoses (14). Together, this results in more than 
20 glycan variants found on the IgG-Fc portion in human sera 
(15). Changes in total Fc-glycosylation, in particular decreased 
galactosylation and sialylation, have been described to contribute 
to a more inflammatory profile of the antibodies and have been 
described in various autoimmune diseases like rheumatoid 
arthritis, systemic lupus erythematosus, and inflammatory 
bowel disease (14, 16, 17). In addition, differences of IgG1 
Fc-glycosylation of antigen-specific antibody subpopulations 
have been described compared to total IgG1 glycoprofiles. These 
changes are highly variable between individuals and are antigen 
dependent (9, 10, 12, 13, 18–21). In addition, marked changes 
of total or antigen-specific IgG1 fucosylation and galactosylation 
were found to correlate with clinical outcome of HDFN and fetal 
or neonatal alloimmune thrombocytopenia (FNAIT), making 
IgG1 glycosylation a possible screening marker for pathological 
IgGs (9, 10, 12, 13, 18). Similar changes for fucosylation have 
recently also been observed in immune response against HIV and 
dengue and have marked clinical consequences (19, 21).
In the studies described above, most work has been performed 
on the most abundant IgG subclass, IgG1 (7, 21–23), with only 
one study investigating glycan released from antigen-specific IgG 
of all subclasses (including potential Fab-glycans) (19). However, 
although most immune responses directed against protein anti-
gens are of the IgG1 subclass, IgG3 responses can also dominate, 
especially early in the immune response, possibly because after 
immunoglobulin class-switching to IgG1 or IgG2-4, descendant 
cells can’t make IgG3 as the IgG3-heavy chain locus has then been 
excised from the genome (24). Theoretically, IgG3+ B-cells can 
however class switch further to IgG1 or to any other IgG class. 
Both indirect and direct experimental evidence for this has been 
obtain as somatic hypermutations seem to increase by subclass 
that mirrors the gene order (3 < 1 < 2 < 4) (25) and by sequencing 
of the resulting switch-region of IgG1 which can contain rem-
nants of not only Sμ-Sγ1-derived sequences, but also Sγ3 (26). 
The tendency for this to occur is likely to depend on the antigen 
(e.g., T-independent antigens class switch directly to IgG2) 
(24), although one study has found remnants of Sγ3 sequences 
in 24% of IgG2 clones, indicating a serial-class switching from 
IgG3 to IgG2. 9% of IgG1 clones showed Sγ3-seqeunces in the 
same study (26). However, both IgG3 and IgG1 responses are 
frequently observed in responses against protein antigens, which 
is a common textbook knowledge for immune responses against 
many blood group antigens involved in alloimmune-mediated 
responses (27, 28).
This is important as the IgG subclasses differ in their ability to initi-
ate phagocytosis via either complement or FcγR binding. IgG3 binds 
FcγRIII and C1q with higher affinity compared to IgG1 and is in some 
cases capable of mediating stronger effector functions via antibody-
dependent cellular cytotoxicity (29, 30) and complement-dependent 
cytotoxicity (29, 31). As these functional features are affected by IgG-
glycosylation (32), it is essential to study the relative glycosylation of 
the subclasses separately during these immune responses, and reveal 
possible glycosylation differences between subclasses. However, this 
is analytically challenging as the peptide backbone encompassing the 
N297-glycosylation site of IgG3, as released by trypsinization, is either 
identical with that of IgG2 or IgG4 depending on the IgG3 allotype (15, 
24). By performing LC separation prior to mass spectrophotometry 
(MS) detection, proper distinction between IgG2 and IgG4 glycosyla-
tion can be performed (15, 33, 34). Previous studies have taken this 
into account and performed analyses on the comparison of IgG1 and 
collective IgG2/3 Fc-glycosylation patterns, showing galactosylation 
and sialylation profiles to be similar for both IgG1 and IgG2/3 during 
childhood and pregnancy (23, 35, 36). However, no study to date has 
reported antigen-specific IgG subclass glycosylation of more than one 
IgG subclass, with IgG3 being hitherto completely ignored (9, 10, 12, 
13, 15, 19, 21, 37).
In the present study, we describe a simple and robust method for 
IgG3 N-glycan analysis. We compare Fc-glycosylation patterns of 
IgG1 and IgG3 for total- and antigen-specific IgG for alloimmune 
responses to Kell as a model for clinical evaluation of antibody 
responses where the IgG1-glycosylation profile has been shown to 
be predictive of disease severity. Immune reaction to this antigen is 
known to be restricted to IgG1 and IgG3 mostly without IgG2 and 
IgG4 (28) responses. Our hypothesis was that if the Fc-glycosylation 
profiles of IgG1 and IgG3 are not identical, then information on 
glycosylation of both subclasses may be required to predict clinical 
outcome in cases where both IgG1 and IgG3 responses are found.
MaTerials anD MeThODs
Patient samples
Patient samples from the prospective OPZI study (Detection 
and Prevention of Pregnancy Immunization) were included 
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after informed consent (3). The OPZI study included all Dutch 
pregnant women with clinically relevant non-D RBC antibodies 
and antigen-negative children. Clinical data (hemoglobin levels 
and treatment with phototherapy or blood transfusion) were 
collected via healthcare workers as described before (3, 12). 
Clinical outcome was divided based on treatment given to the 
newborn in three groups: (i) severe (defined by an intrauterine 
or post-delivery blood transfusion given to the fetus or newborn, 
respectively), (ii) moderate (phototherapy was given to the new-
born), or (iii) healthy (no treatment given to the newborn).
Purification of anti-K antibodies from sera
Anti-K alloantibodies from K-negative pregnant women were 
purified after incubation with K-positive RBCs as described 
before (12), and obtained after elution with a mild acid buffer. 
These women had earlier been diagnosed and confirmed with 
anti-K antibodies by Sanquin Diagnostics. In few cases, other 
antibodies than anti-K were identified, in which case anti-K puri-
fication was performed with K+ RBC but negative for the other 
antigen(s). The amount of IgG1 and IgG3 in the eluate and serum 
was determined by ELISA on 96-well plates (NUNC-Immuno, 
Maxisorp, Roskilde, Denmark) coated with either mouse-anti-
human IgG1 Fc (clone M1325, Sanquin Reagents, Amsterdam, 
the Netherlands) or mouse-anti-human IgG3 hinge (clone M270, 
Sanquin Reagents). Fully human recombinant antibodies [IgG1κ 
and IgG3 GDob1 (38)] were used as standards to calculate 
the IgG1 and IgG3 concentrations. Eluates were considered to 
contain purified IgG1 and IgG3 when all negative controls were 
below a certain threshold.
Purification of igg1 from sera and 
antigen-specific igg1 and igg3 from rBc 
eluates
IgG1, IgG2/IgG3, and IgG4 (total IgG) were isolated from 
serum using 15 µL protein G Sepharose 4 Fast Flow beads (GE 
Healthcare Life Sciences, Uppsala, Sweden) as described earlier 
(9). Eluates from serum-opsonized K+ RBC containing anti-K 
specific IgG1 and IgG3 were purified as described previously by 
affinity chromatography, using 15 µL protein G Sepharose 4 Fast 
Flow beads (GE Healthcare Life Sciences, Uppsala, Sweden) in 
a 96-well plate (9). IgG1 and IgG3 glycopeptides were separated 
based on elution time and mass using liquid chromatography-
mass spectrometry (LC-MS).
Purification of igg3 from sera
IgG3 was isolated from serum in a 96-well sterile Multiscreen 
HTS plate (Milipore Corporation, Billerica, MA, USA). First, 
to remove IgG1, IgG2, and IgG4, 4 µL of serum was applied to 
20 µL protein-A 4 Fast Flow beads (GE Healthcare Life Sciences, 
Uppsala, Sweden) in 150 µL of PBS, followed by a 1-h incubation 
at room temperature while shaking at 1,000  RPM (Heidolph 
Titramax 100, Namur, Belgium), using wells without protein-A 
beads as negative control. IgG3 was collected in the flow through 
after filtration. Next, 2.5 µL CaptureSelect™ IgG3 (Hu) affinity 
beads were added to the flow through and incubated for 1  h 
with shaking at 1,000  RPM (Heidolph Titramax 100, Namur, 
Belgium). IgG isolated from mixed control serum with protein G 
Sepharose 4 Fast Flow beads and PBS blanks without the addition 
of serum were used as controls. Plates were washed three times by 
filtration with 200 µL PBS, followed by three washing steps with 
200 µL deionized water using a vacuum manifold. Bound IgG3 
was eluted with 100 µL of 100 mM formic acid (Fluka, Steinheim, 
Germany) into a V-bottom microtitration plate (Nunc) using a 
vacuum manifold. Samples were dried in a vacuum concentrator 
at 45°C for 2.5 h.
Mass spectrometry analysis of igg1 and 
igg3
The purified IgG1 and IgG3 were digested with initial shaking 
for 5 min followed by overnight incubation at 37°C with 20 µL 
0.005  µg/µL trypsin (sequencing grade; Promega, Leiden, the 
Netherlands) in 25 mM ammonium bicarbonate. Samples were 
stored at −20°C until measurement. Analysis of purified tryptic 
IgG Fc-glycosylation was performed with nanoLC reversed-phase 
electrospray (ESI)-quadrupole time-of-flight (QTOF)-MS on an 
Ultimate 3000 RSLCnano system (Dionex/Thermo Scientific, 
Breda, the Netherlands) coupled to a Maxis Impact QTOF-MS 
(Bruker Daltonics, Bremen, Germany) as described previously 
(39).
Data processing was performed using LaCyTools (40). Separate 
analyte curation was performed for IgG1 and IgG3 for both serum 
and eluates. Tryptic IgG1 glycopeptides contained the peptide 
sequence EEQYNSTYR, while the peptide sequence for IgG3 var-
ied according to allotype: the majority of the samples contained 
EEQFNSTFR, while two showed high signals for EEQFNSTYR 
(41). A list of N-glycopeptides were included in the LaCyTools 
analysis based on both characterization of the data and current 
knowledge of potential IgG glycans; N-glycopeptides were then 
excluded if either the average mass error of the 3+ charge state 
was below −10 or above 10 ppm, if the signal-to-noise ratio was 
above 9 or if the measure of isotopic pattern quality deviated over 
0.35. A complete list of the N-glycopeptides which were included 
in the final analysis can be found in Table S1 in Supplementary 
Material. For each analyte, the area of the first x isotopic peaks 
was extracted for which the total signal amounted to at least 85%. 
A correction was then applied so that the values reflected 100% 
signal intensity. Signal intensities for various charge states were 
summed. The absolute intensities of the included analytes were 
normalized to the total area for IgG1 and IgG3 separately. For 
both IgG1 and IgG3, derived traits were calculated, showing the 
fraction of fucosylated, galactosylated and sialylated glycans, and 
glycans carrying a bisecting GlcNAc (the exact calculations are 
shown in Table S2 in Supplementary Material).
statistical analysis
The derived traits as dependent variables tested not to be 
normally distributed using IBM SPSS 23.0 (IBM, Armonk, NY, 
USA). Linear regression was performed for correlating IgG1 
to IgG3 Fc-glycosylation. Paired t-testing was performed com-
paring IgG1 and IgG3 Fc-glycosylation and Spearman rank to 
correlate Fc-glycosylation with Hb level. Fc-glycosylation was 
correlated to disease severity using one-way ANOVA testing 
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with Bonferroni correction for multiple comparison. To further 
analyze the predicting value of both IgG1 and IgG3, we calculated 
the glycosylation of IgG1 and IgG3 combined as (relative anti-K 
IgG1 glycosylation)  *  ([IgG1 anti-K])/([IgG1 anti-K]  +  [IgG3 
anti-K]) + (relative anti-K IgG3 glycosylation) * ([IgG3 anti-K])/
([IgG1 anti-K] + [IgG3 anti-K]), where [IgG] is the concentra-
tion of the indicated subclass anti-K found in the RBC eluates. 
The reported p-values were considered statistically significant 
when below 0.05. The statistical tests were performed using SPSS 
23.0 and GraphPad Prism version 6.00 for Windows (GraphPad 
Software Inc., La Jolla, CA, USA) and IBM SPSS Statistics for 
Windows version 23.0 (IBM Corp., Armonk, NY, USA).
resUlTs
antigen-specific anti-K Fc-glycosylation 
compared to Total igg
Both anti-K-specific and total serum IgG1 and IgG3 were purified 
from 30 pregnant women and the concentration of the purified 
anti-K IgG1 and IgG3 were quantified by ELISA (Table S3A in 
Supplementary Material). These eluates were digested with trypsin 
and the glycopeptides were subsequently analyzed by mass spectrom-
etry. IgG1 Fc-glycosylation profiles were analyzed using a recently 
developed data processing tool employing additional quality assess-
ment options (42) yielding results comparable to those obtained with 
a previous, less elaborate approach, yielding comparable results (12) 
(Figure 1). We then compared the antigen-specific glycosylation lev-
els for IgG3 with the glycosylation level for total IgG3. Both total IgG3 
and antigen-specific IgG3 were successfully obtained for 24 samples. 
Similar to IgG1-anti-K antibodies, IgG3-anti-K galactosylation, 
sialylation, and fucosylation were found to be decreased compared 
to total IgG3, while anti-K bisection was increased (Figure 2).
Fc-glycosylation of Total igg3 and igg1 
are highly similar within each individual
To analyze whether the glycosylation profiles of IgG1 and IgG3 
were similar within an individual, we performed a linear regres-
sion analysis. A reliable IgG1 and IgG3 mass spectrometry result 
was obtained for 27 of these women. Glycosylation profiles of total 
IgG1 correlated significantly with those of total IgG3 for fuco-
sylation, bisection, galactosylation, and sialylation (p < 0.0001) 
(Figure 3A).
However, the Fc-glycosylation profiles of total IgG1 and IgG3 
were significantly different, except for galactosylation (71 vs. 70%) 
(Figure S1A in Supplementary Material). Quantitatively, these 
differences were only marginal for fucosylation and bisection 
(89.9 vs. 91.1%, p = 0.002 and 12.8 vs. 13.3%, p = 0.023, respec-
tively, for IgG3 vs. IgG1), while sialylation was found to be much 
higher in IgG3 compared to IgG1 (16.3 vs. 11.8%, p < 0.0001).
antigen-specific igg-glycosylation 
responses are highly analogous between 
igg3 and igg1
The Fc glycopeptides of purified antigen-specific anti-K IgG1 
and IgG3 were also compared with each other (Figure 3B). The 
glycosylation profiles of anti-K specific IgG1 and IgG3 were also 
highly similar within individuals, which showed significant corre-
lations between these subclasses for fucosylation, galactosylation, 
and sialylation, but not for bisection (Figure 3B). Fucosylation 
and galactosylation of antigen-specific anti-K antibodies was 
not significantly different between IgG1 and IgG3 (Figure S1B 
in Supplementary Material). Bisection was significantly increased 
for IgG3 compared to IgG1. In line with our findings for total 
serum IgG3, the most pronounced difference was found for 
sialylation, being higher in IgG3 compared to IgG1 (Figure S1B 
in Supplementary Material).
Fc-glycosylation and antibody levels of 
igg1 and igg3 Predict clinical Outcome
Of the anti-Kell positive mothers, 17 gave birth to an antigen-
positive child, making them at risk for HDFN (Table S3B in 
Supplementary Material). We attempted to improve the predic-
tion of clinical outcome by combining the Fc-glycosylation levels 
of K-specific-IgG1 and IgG3 antibodies adjusted for the IgG1 
and IgG3 concentration present (Table S3A in Supplementary 
Material). Due to the low sample size, a multiparametric 
analysis, such as stepwise forward multiple regression analysis 
including both titer and glycosylation levels, was not possible 
for meaningful analysis of these relationships with disease out-
come, in this case hemolysis by anti-K in the affected fetuses. 
We therefore performed a Spearman rank correlation including 
Hb as outcome measurement, taking the glycosylation features 
of anti-K IgG1 (Figure 4A), IgG3 (Figure 4B), or weighted for 
the relative abundance of anti-Kell IgG1 and IgG3 present in the 
eluate (Figure  4C). Only the level of IgG1 galactosylation and 
the combined Fc-galactosylation of anti-Kell IgG1 and IgG3 level 
correlated in a comparable way with Hb level (Figures  4A,C). 
A borderline significant correlation was found for fucosylation 
and bisection, while no correlation was found for sialylation. 
However, based on the treatment given to the newborn, low 
fucosylation, low bisection, and high galactosylation did associ-
ate significantly with disease severity for IgG1 glycosylation alone 
and for the combined anti-Kell IgG1 and IgG3 Fc-glycosylation 
levels (Figures  5A,C) but not for IgG3 Fc-glycosylation alone 
(Figure 5B).
DiscUssiOn
In this study, we analyzed Fc-glycosylation of IgG1 and IgG3 
for both total serum and antigen-specific antibodies of 30 
patient samples using mass spectrometry. We found that 
whereas the glycosylation profiles of both total and antigen-
specific IgG1 and IgG3 are very similar within an individual, 
subtle differences exist, most pronounced for sialylation. In 
addition, we found that the relative levels of Fc-glycosylation 
for IgG1 and IgG3 combined only gave a marginally better pre-
diction of clinical outcome compared to IgG1 Fc-glycosylation 
alone. Combined, this suggests that analysis of the dominant 
subclass in each individual (mostly IgG1) is sufficient to deter-
mine Fc glycosylation and assess its association with clinical 
parameters.
FigUre 1 | Examples of IgG1 and IgG3 Fc N-glycan structures showing skewing of anti-K Fc-glycosylation compared to total immunoglobulin G (IgG). (a)  
A schematic structure of the diantennary glycan found in human IgG. Blue square, N-acetylglucosamine; red triangle, fucose; green circle, mannose; yellow gray 
circle, galactose; purple diamond, N-acetylneuraminic (sialic) acid. (B,c) Mass spectrometric analysis of Fc glycopeptides encompassing N297 of IgG1 (B) and IgG3 
(c). Spectra from a representative patient are shown, with mass/charge ratio (m/z) of the glycopeptides on the x-axis and relative abundance on the y-axis. 
Asterisks indicate non-glycopeptide signals.
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IgG3 glycosylation has not been extensively compared in 
normal individuals to that of IgG1 due to technological chal-
lenges, but like in this study similar glycosylation features to 
that of human IgG1 has been reported (15). The most prominent 
difference between the Fc glycan features of IgG1 and IgG2 we 
observed was the higher sialylation seen in IgG3. This may 
FigUre 2 | IgG1 and IgG3 antibodies show skewing of anti-K Fc-glycosylation compared to total immunoglobulin G (IgG). Glycosylation features found in 
alloantibodies against the Kell antigen. Total (x-axis) vs. antibody specific (y-axis) IgG1 (a) and IgG3 (B) shows a decreased anti-K fucosylation, galactosylation, and 
sialylation and increased bisection compared to total IgG. Statistical analysis was done using a paired t-test.
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simply reflect different accessibilities of the Fc-N-glycan for 
different processing enzymes in the Golgi, due to differences in 
the quaternary structure of the Fc protein portions. An alterna-
tive explanation for the elevated IgG3 sialylation may also be 
that IgG3-Fc-sialylation is differently affected by either plasma 
sialidases or sialyltransferases (43) or increased upon the induc-
tion or boosting of immune responses, something that several 
studies have found both in mice and in humans (44, 45). As IgG3 
is often made early against protein antigens but later disappear 
if they sequentially class switch to downstream subclasses or 
isotypes (24, 26), this may possibly explain the elevated sialyla-
tion in IgG3.
Although human IgG1-type antibody Fc-glycoprofiles have 
been studied in a handful of specific immune responses including 
infectious (14, 37, 44) and alloimmune diseases (9, 10, 12, 13), this 
is the first study that takes IgG3 into account and relates this to 
IgG1 glycosylation. Whereas IgG1 antibodies have almost exclu-
sively high levels of core fucose, antigen-specific IgG1 antibodies 
in various alloimmune and some specific infectious diseases can 
display low levels of core fucosylation, although wide variation 
between different individuals is observed (10, 12, 13, 19, 21). 
Therefore, we hypothesized that a comprehensive study of alloan-
tibodies against RBCs would enable us to investigate whether the 
production of low core fucosylated IgG occurs already at the IgG3 
level or whether this glycoprofile is restricted to IgG1. Indeed, we 
found that the remarkable changes Fc fucosylation were similar 
for IgG1 and IgG3. In a previous study analyzing anti-K IgG1 
Fc-glycosylation profiles of the same samples but using different 
data extraction techniques, we found similar trends, although the 
level of significance varied. The increased anti-K bisection was 
not observed in the previous study (12) but was detected in the 
current study using improved data processing and data curation 
methods (42).
We realize that our observation on specific immune 
responses is based only on alloantibodies against anti-K. 
Since similar trends were observed for total IgG, representing 
all IgG-responses within a given individual, this suggests the 
association between IgG1 and IgG3 glycosylation is a general 
phenomenon, but this has to be confirmed in other antigen-
specific immune responses. The patients studied, formed the 
IgG response after transfusion or during pregnancy, with 
both immune responses giving similar responses in terms 
of glycosylation, including lowered core fucosylation (12). 
Similar responses were also observed in pregnancy and in 
voluntary immunized males against the RhD antigen (46). The 
pregnancy itself, the time of sampling, is also known to be a 
cause of elevated galactosylation and sialylation of IgG-Fc in 
general (10) that might theoretically mask any changes applied 
to antigen-specific IgG. Nevertheless, we have reported previ-
ously that the antigen-specific galactosylation—even in preg-
nancy—can be either increased or decreased compared to the 
total IgG galactosylation and sialylation. We now report that 
antigen-specific glycosylation features between IgG1 and IgG3 
also strongly correlate within a given individual, despite this 
general tendency for temporal elevation in IgG galactosylation 
and sialylation during pregnancy.
FigUre 3 | Correlation between IgG1 and IgG3 Fc-glycosylation for total and anti-K specific immunoglobulin G (IgG). Total (a) and anti-K (B) IgG1 (x-axis) vs. IgG3 
(y-axis) Fc-glycosylation shows a significant correlation between fucosylation, bisecting GlcNAc, galactosylation, and sialylation except for anti-K bisecting GlcNAc. 
The dotted line indicates the line of identical IgG1 and IgG3 glycosylation and illustrates the similarity of total IgG1 and IgG3 glycosylation, except for sialylation 
which seems higher in IgG3. Statistical analysis was done using a linear regression analysis.
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The observed similarities in IgG1 and IgG3 glycosylation, 
both for total and in particular for antigen-specific responses, 
suggest that the regulation of glycosylation in B cells and plasma 
cells remains largely unaltered after class-switching from IgG3 to 
IgG1, at least for anti-K alloantibodies. If this can be confirmed 
for other immune responses, this suggests that the type of gly-
cosylation machinery within a B cell may be determined at the 
moment of first encounter of the antigen and is largely retained 
during differentiation and expansion. The existence of an 
immunological memory for Fc-glycosylation is supported by our 
previous observations that the Fc-glycoprofiles of alloantibodies 
remain stable for over 7 years post-delivery (10), are maintained 
between pregnancies in FNAIT mothers (13) or during booster 
responses in hyperimmune anti-D donors (46). Together, this 
implies that glycosylation features of immunoglobulins are con-
served after class-switching, either directly from an IgM-memory 
cell to IgG1 or IgG3, or from IgG3 to IgG1, and so are the altered 
functional properties of IgG1 and IgG3 inferred through these 
glycan changes (46).
Of the observed glycosylation differences, two are known 
to have effect on Fc-receptor or complement binding and 
subsequent functions. Fucose is known to be the most critical 
glycan component, with afucosylation inducing a strong increase 
in cytotoxicity of all IgG through elevated binding to FcγRIIIa 
and FcγRIIIb (10, 32, 47–49). Human IgG1 galactosylation has 
been implied to also enhance the effector function of IgG, with 
increased galactosylation enhancing binding to FcγRIIIa (8, 32) 
and C1q (11, 32), which is supported by clinical studies analyz-
ing antigen-specific Fc-galactosylation (12, 13, 20, 37, 50). The 
impacts of these glycan changes on IgG3 functions are mostly 
unexplored. To our knowledge, the only documented cases is 
our recent study where we found that the effect of fucosylation 
on human FcγRIIIa/b binding is conserved for all human IgG 
subclasses (49), especially between IgG1 and IgG3. Given the 
extreme homologies between both FcγR- and C1q interactions 
between the IgG1 subclasses (24), the dependencies on interac-
tions on glycan alterations is likely to be highly conserved, but 
still need verification.
Since IgG1 and IgG3 glycoprofiles correlated strongly with 
each other and are generally highly similar, one may hypoth-
esize that glycoprofiles of either IgG1 or IgG3 would suffice to 
get a qualitative impression of the immune response. However, 
individual differences were noted, and it has been shown in other 
studies that in some cases, also seen here, that IgG1 and IgG3 can 
be found exclusively or predominantly (24). This is particularly 
important for analysis of clinically relevant anti-RBC antibodies, 
for example in pregnancy, when either or both IgG subclasses 
are frequently found. Here, we therefore analyzed both IgG1 
and IgG3 Fc-glycosylation in relation to clinical outcome. In 
this study, only two women had far higher IgG3 levels than 
IgG1, with both women being sampled before giving birth to 
a Kell negative child, and are thus not clinically relevant. Since 
none of the maternal samples at risk for giving birth to a child 
with HDFN had a very high IgG3 concentration, the effect of 
FigUre 4 | High galactosylation correlates with low Hb level. (a) Anti-K IgG1, (B) IgG3 glycosylation, and (c) the combination of IgG1 and IgG3 Fc-glycosylation 
and antibody level (y-axis) correlated to Hb level (x-axis). Galactosylation shows a significant correlation with Hb level for (a) anti-K IgG1 and (c) the combination of 
IgG1 and IgG3 Fc-glycosylation and antibody level. Statistical analysis was done using Spearman rank correlation.
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IgG3 Fc-glycosylation was expected to be limited. Indeed, no 
additional value for predicting Hb level of the newborn was 
found using both relative IgG1 and IgG3 Fc-glycosylation lev-
els as compared to IgG1 alone. Disease severity based on the 
treatment given to the newborn was most strongly associated 
with IgG1 galactosylation alone, but also with the combination 
of relative IgG1 and IgG3 galactosylation. These findings are 
in line with previously found associations between allo- and 
auto-RBC specific IgG1 glycosylation and Hb level as well as 
disease severity (12), and also with results for FNAIT (13). Low 
anti-RhD, anti-Kell and anti-HPA-1a IgG1 fucosylation and high 
galactosylation and sialylation of anti-Rhc and anti-auto-RBC 
IgG1 were found to correlate with more severe disease (9, 12).
Although in the current study the samples originated from 
a very large cohort including 679 pregnancies with anti-RBC 
antibodies, a possible limitation of this study is the small sample 
size and the western European (Dutch) origin of the subjects. Of 
the 679 included pregnancies, 230 were antigen positive (18 Kell, 
117 Rhc, and 95 RhE) of which only 17 gave birth to a K-positive 
child, because the majority of the antibodies was provoked by 
a previous blood transfusion rather than by a K-positive child 
(12). Further analysis should be performed including a larger 
cohort, including non-pregnant subjects, of which clinical data 
are available.
In conclusion, this study shows that antigen-specific IgG1 and 
IgG3 responses in terms of their Fc-glycosylation are in general 
FigUre 5 | Low bisection and high galactosylation correlate with worse clinical outcome. (a) Anti-K IgG1, (B) IgG3 glycosylation, and (c) the combination of IgG1 
and IgG3 Fc-glycosylation and antibody level (y-axis) correlated to disease severity (x-axis). Bisection and galactosylation show a significant correlation with disease 
severity. There is no correlation between fucosylation or sialylation and disease severity. Statistical analysis was done using one-way ANOVA with Bonferroni 
correction for multiple comparison testing.
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highly similar, with the exception of sialylation which was higher 
for IgG3 compared to IgG1. The remarkable reduction in core 
fucosylation seen previously in antigen-specific responses against 
both platelet and RBC antigens is also seen to a similar degree for 
IgG3. This indicates that the decision to produce low-fucosylated 
IgG is taken early in the immune response and that this informa-
tion can be carried over by sequential class-switching from IgG3 
producing cells to IgG1—which is known to occur (26)—showing 
signs of immunological memory as it is stable for years (10, 13, 
46). Our previous work has indicated that glycosylation, espe-
cially fucosylation and galactosylation, were at least as important 
as antibody titer in determining clinical outcome (9, 12, 46), 
while others have shown that IgG1 and IgG3 have similar clinical 
activities (51). We found no improved prediction of the clinical 
outcome when including both IgG1 and IgG3 Fc-glycosylation 
levels, most likely because IgG3 concentrations are often low 
and associated glycosylation profiles are similar to those of IgG1. 
The danger of excluding IgG3 from analysis is that some cases 
have responses consisting almost exclusively of IgG3. However, 
the frequency of such cases is low, suggesting that monitoring 
IgG1 Fc-glycosylation profiles is sufficient for predicting disease 
severity in alloimmune-mediated diseases such as HDFN.
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